专业监测看板

Testing Nivolumab and Ipilimumab Immunotherapy With or Without the Targeted Drug Cabozantinib in Recurrent, Metastatic, or Incurable Nasopharyngeal Cancer

药物 / 成分：Biospecimen Collection、Cabozantinib S-malate、Computed Tomography、Ipilimumab

登记的停止原因（原文）：Scheduled Interim Monitoring

Trial of Novel Regimens for the Treatment of Pulmonary Tuberculosis

药物 / 成分：Isoniazid、Rifampicin、Pyrazinamide、Ethambutol

登记的停止原因（原文）：Temporarily Closed (Paused) to Accrual.

Phase 2, Single-arm Trial of BMS-986340 in Association With Nivolumab, Trifluridine/Tipiracil and Bevacizumab for Patients Refractory to Standard of Care Treatment and With Microsatellite-stable Colorectal Cancer

药物 / 成分：Nivolumab、Bevacizumab、BMS-986340、Trifluridine + Tipiracil

登记的停止原因（原文）：PI Request

Adaptive Radiation for Abdominopelvic Metastases

药物 / 成分：Adaptive Stereotactic Body Radiation

登记的停止原因（原文）：Pending interim analysis

Effects of Home Base Whole-body Vibration in Osteoarthritis. (VIBE-Rx2)

药物 / 成分：Sub Acute Whole Body Vibration Training

登记的停止原因（原文）：funding issues

Clinical Performance of the VESTO® Vascular Stent for Treatment of Iliac Peripheral Obstructive Arterial Disease

药物 / 成分：Vascular Stent - Vesto Endoprosthesis

登记的停止原因（原文）：Low recruitment potential, limiting the feasibility of achieving the planned sample size.

Automated Oxygen Titration With the EMILY.AI Device in a Respiratory Intermediate Care Unit

药物 / 成分：Emily.AI、Manual oxygen titration

登记的停止原因（原文）：Recruitment temporarily paused pending competent authority (AEMPS) approval of a protocol amendment. Recruitment will resume after approval. Not stopped for safety reasons.

CS1-CAR T Therapy Following Chemotherapy in Treating Patients With Relapsed or Refractory CS1 Positive Multiple Myeloma

药物 / 成分：CS1-CAR T Therapy、Cyclophosphamide、Fludarabine、Leukapheresis

登记的停止原因（原文）：Slow/Low Accrual

Study Using Hyperpolarized 13C-Pyruvate Magnetic Resonance Spectroscopic Imaging in Patients With Pancreatic Cysts Undergoing Surgical Resection

药物 / 成分：Hyperpolarized 13-C-pyruvate

登记的停止原因（原文）：PI Request

PEP-CMV + Nivolumab for Newly Diagnosed Diffuse Midline Glioma/High-grade Glioma and Recurrent Diffuse Midline Glioma/High-grade Glioma, Medulloblastoma, and Ependymoma

药物 / 成分：PEP-CMV vaccine、Tetanus booster、Nivolumab、Temozolomide

登记的停止原因（原文）：Drugs/Equipment Unavailable

HEARTS Trial for Thoracic Cancers

药物 / 成分：MRgART、LINAC

登记的停止原因（原文）：Funding issues

ORCHARDS-AIR Study

药物 / 成分：Nasal swab、Indoor air quality monitor

登记的停止原因（原文）：for the summer, continue enrollment this fall

Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR Trial

药物 / 成分：Atezolizumab、Biospecimen Collection、Computed Tomography、Magnetic Resonance Imaging

登记的停止原因（原文）：Scheduled Interim Monitoring

Molecular and Clinical Profile of Diabetes Mellitus and Its Complications

登记的停止原因（原文）：Recruitment temporarily paused.

Evaluation of Cardiac Function With Cardio-respiratory Synchronized MRI

药物 / 成分：cardiovascular MRI (CMR)、Conventional Cardiologic Evaluation

登记的停止原因（原文）：COVID-19

Hypoproteic Diet in Acromegaly

药物 / 成分：Usual clinical practice + hypoproteic diet

登记的停止原因（原文）：ethical issue

The Iowa ACEs and Sleep Cohort and Manipulating Sleep in Young Adults With ACEs Studies

药物 / 成分：Cognitive Behavioral Therapy for Insomnia (CBT-i)

登记的停止原因（原文）：Enrollment temporarily paused while the PI and award transfer from the University of Iowa to the University of Wisconsin-Madison. Recruitment will resume after UW-Madison IRB approval and award activation (anticipated early 2027).

Adaptive Radiation Therapy for Men With Intermediate- or High-Risk Prostate Cancer

药物 / 成分：adaptive stereotactic body radiation therapy (SBRT) with a SIB

登记的停止原因（原文）：Pending interim analysis

A Vaccine (Ad5.F35-hGCC-PADRE) for the Treatment of Gastrointestinal Adenocarcinoma

药物 / 成分：Adenovirus 5/F35-Human Guanylyl Cyclase C-PADRE

登记的停止原因（原文）：Protocol is with FDA review, waiting for funding to be released

A Study of Poziotinib in Previously Treated Participants With Locally Advanced or Metastatic NSCLC Harboring HER2 Exon 20 Mutations

药物 / 成分：Poziotinib、Docetaxel

登记的停止原因（原文）：The study has not enrolled any patients. The study design is under discussion and will likely be redesigned in consultation with the FDA.